Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026
Same author

ASO Visual Abstract: From Clinical Trial Awareness to Practice-Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.

Annals of surgical oncology·2026
Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Multidisciplinary Clinics in Cancer-Models, Metrics, and Meaning: A Review.

The oncologist·2026
Same author

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort.

JNCI cancer spectrum·2026
Same author

ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.

Annals of surgical oncology·2026
Same journal

Mast cell proteases and their significance in physiology, pathology, and therapeutic approaches.

Pharmacological reviews·2026
Same journal

Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.

Pharmacological reviews·2026
Same journal

Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic.

Pharmacological reviews·2026
Same journal

Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.

Pharmacological reviews·2026
Same journal

International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.

Pharmacological reviews·2026
Same journal

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Targeting Immune Checkpoints in Hematologic Malignancies.

Gheath Alatrash1, Naval Daver2, Elizabeth A Mittendorf2

  • 1Departments of Stem Cell Transplantation and Cellular Therapy (G.A., E.A.M.), Leukemia (N.D.), and Breast Surgical (E.A.M.) Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas galatras@mdanderson.org.

Pharmacological Reviews
|September 25, 2016
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors targeting CTLA-4 and PD-1 show promise for blood cancers. Further research is needed to overcome challenges and integrate this therapy into standard care for hematologic malignancies.

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 14, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapy

Background:

  • Immune checkpoint inhibitors targeting CTLA-4 and PD-1 have transformed solid tumor treatment.
  • Their application in hematologic malignancies is an unmet clinical need.
  • Hematologic cancers present unique challenges and opportunities for immune checkpoint inhibition.

Purpose of the Study:

  • To review the potential of immune checkpoint inhibition in hematologic malignancies.
  • To discuss considerations for implementing this therapy in blood cancers.
  • To highlight ongoing research and future directions.

Main Methods:

  • Review of existing clinical trials and scientific literature.
  • Analysis of the unique characteristics of hematologic malignancies in relation to immune response.
  • Discussion of challenges and potential benefits of immune checkpoint blockade.

Main Results:

  • Hematologic malignancies often express targetable immune checkpoint molecules.
  • Allogeneic stem cell transplantation demonstrates the immune responsiveness of these cancers.
  • Clinical trials show potential for immune checkpoint inhibitors before and after allo-SCT.

Conclusions:

  • Immune checkpoint inhibition holds significant promise for treating hematologic malignancies.
  • Addressing challenges related to immune organ restoration is crucial.
  • This approach is expected to become a standard of care for blood cancers.